Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

CNS Neurosci Ther 2013 May;19(5):302-6

Department of Neurology and Center for Clinical Neuroscience, Charles University, General Hospital, Prague, Czech Republic.

Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cns.12101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493348PMC
May 2013
52 Reads

Publication Analysis

Top Keywords

patients multiple
8
multiple sclerosis
8
prolonged-release fampridine
8
fampridine
5
clinical practice
4
nervous system
4
system fampridine
4
fampridine approved
4
practice prediction
4
prediction evaluation
4
demyelinated axons
4
axons central
4
approved improve
4
central nervous
4
speed walking
4
statement summary
4
summary data
4
data fampridine
4
fampridine recommendations
4
practical medication
4

Similar Publications